Abbvie Inc. vs BridgeBio Pharma, Inc.
ABBV vs BBIO — side-by-side comparison from reported financials. ABBV leads 7, BBIO leads 2 of 9 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
BridgeBio Pharma, Inc.
BBIO · Healthcare
$65.35+0.48%Strained
| Metric | ABBV | BBIO |
|---|---|---|
| Price | $276.43 | $65.35 |
| Market cap | $488B | $12.8B |
| Revenue (TTM) | $64.4B | $713M |
| Revenue growth | +1.8% | +86.3% |
| Net margin | 9.8% | -97.0% |
| Free cash flow | $18.2B | -$435M |
| Net cash (debt) | ($56.2B) | ($1.26B) |
| 1-year price return | +19.8% | +19.3% |
| P/E | 77.4 | — |
| P/E vs own history (cheap-side %) | 23% | — |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -207% |
| Altman Z-score | 2.33 | -2.72 |
| CV checks passed | 9 of 11 | 3 of 11 |
| Employees | 57,000 | 839 |
Full résumé-style profiles: ABBV CV · BBIO CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.